Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
April 08 2022 - 1:00AM
Business Wire
The Annual General Meeting will be
broadcasted live by the Company
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) will hold its Annual
General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST
on May 20, 2022 in its headquarters, 117 avenue de Luminy, F-13009
Marseille. The Annual General Meeting will be broadcasted live.
The Notice of Meeting of this AGM was published on April 8, 2022
in the French legal bulletin. It includes the agenda, the proposed
resolutions as well as instructions to participate and vote in this
AGM.
All documentation regarding this AGM will be published on the
Company’s website along with the dial-in details for the live
broadcast.
Precision regarding the AGM:
Only shareholders having registered their shares at least two
business days prior to the date of the AGM, by zero hour Paris
time, will be able to participate.
Shareholders holding “au porteur” (bearer) shares will need to
obtain an “attestation de participation” (certificate of
shareholding) from their brokers. This “attestation de
participation” must be attached to the voting or proxy form.
Written questions from shareholders must be received the second
business days prior to the AGM at the latest (by e-mail to
investors@innate-pharma.fr).
Shareholders may obtain the legal documentation in preparation
of the AGM (as described in article R. 225-83 of the French Code de
Commerce) by sending a request by e-mail to
investors@innate-pharma.fr.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France, with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2021, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public, by
the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220407005717/en/
For additional information, please contact:
Investors and Media Innate
Pharma Henry Wheeler
Tel.: +33 (0)4 84 90 32 88 Henry.wheeler@innate-pharma.fr ATCG
Press Marie Puvieux (France) Tel.: +33 981 87 46 72
innate-pharma@atcg-partners.com
Innate Pharma (EU:IPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From Apr 2023 to Apr 2024